To identify circulating factors as candidates involved in type 2 diabetes mellitus (T2DM), we conducted two different quantitative proteomic analyses: (1) db/db mouse sera were compared with db/+ mouse sera obtained at 4, 8, 12, and 24 weeks of age, and (2) db/db mouse sera from animals treated with liraglutide were compared with sera from animals without liraglutide treatment. Twenty proteins were differentially expressed in db/db mouse sera in the first experiment and eight proteins were differentially expressed in db/db mouse sera after liraglutide treatment in the second experiment. Soluble epidermal growth factor receptor (sEGFR) was identified as a common factor, and its protein level was significantly affected in both experiments. An enzyme-linked immunosorbent assay confirmed that the relatively low serum sEGFR levels in db/db mice were restored by liraglutide treatment. The serum sEGFR levels were elevated in diabetic mice with impaired insulin secretion and decreased in high-fat diet-fed mice and ob/ob mice. The serum sEGFR levels increased after the administration of a dual inhibitor of IGF-1/insulin receptor or streptozotocin. In humans with normal glucose tolerance or T2DM, the serum sEGFR levels were correlated with the fasting blood glucose, fasting serum insulin, homeostatic model assessment of insulin resistance, HbA1c, total cholesterol, low-density lipoprotein cholesterol, and triglycerides levels. These findings suggest that sEGFR might be a biomarker for evaluating insulin resistance or a therapeutic target of liraglutide. (Endocrinology 158: 4152-4164, 2017) 
A number of humoral factors are involved in the development and progression of type 2 diabetes mellitus (T2DM) through interorgan cross talk (1) . The identification of circulating factors that reflect diabetic conditions has the potential to advance our understanding of pathogenesis and to further the development of therapeutic strategies for diabetes. In addition, biomarkers that indicate the therapeutic efficacy of diabetes treatments are very useful for diabetic patients, especially those with pre-or early-stage T2DM.
Several reports have explored the serum proteins of diabetic model rodents, such as db/db mice (2), streptozotocin (STZ)-induced diabetic rats (3) (4) (5) , KK-(A)y mice (6) , and Otsuka Long-Evans Tokushima Fatty rats (7), as well as human patients with diabetic complications such as retinopathy (8) , nephropathy (9, 10) , and cardiovascular disease (11) . Thus, proteomics is now widely used for diabetic research; to our knowledge, however, chronological changes and changes in markers after treatment with antidiabetic agents have not been previously studied.
In this study, we used a quantitative serum proteomic approach to examine db/db mice, a widely used model for investigating the pathogenesis of diabetes and diabetic complications. These mice possess a mutation in the leptin receptor gene (12) , causing them to exhibit morbid obesity, hyperglycemia, and insulin resistance gradually with age and ultimately to develop diabetic complications, such as neuropathy, retinopathy, nephropathy, and cardiovascular disease. Liraglutide, an antidiabetic agent, has both pancreatic effects by modulating insulin and glucagon secretion and extrapancreatic effects, which include an improvement in hepatic insulin sensitivity (13) and protective effects against cardiovascular complications (14) . To identify biomarkers that are involved in the development, progression, and treatment of diabetes and/ or diabetic complications, we explored the comprehensive serum proteome at different ages and in liraglutidetreated db/db mice using a proteomic technique, as follows: (1) db/db mouse sera were compared with db/+ mouse sera obtained at 4, 8, 12 , and 24 weeks of age, and (2) db/db mouse sera from animals treated with liraglutide for 2 weeks were compared with sera from animals without liraglutide treatment. Soluble epidermal growth factor receptor (sEGFR) was identified as a common factor, the protein level of which was significantly reduced across all ages in the db/db mice and was restored by treatment with liraglutide. We further investigated the changes in serum sEGFR levels in several diabetic mouse models and human subjects with or without diabetes.
Materials and Methods

Animals and animal care
Male C57BL/6J wild-type mice, which were obtained from CLEA Japan, were fed either normal chow (Oriental Yeast, Tokyo, Japan) or a high-fat diet (High Fat Diet 32; CLEA Japan, Tokyo, Japan) from 8 weeks of age to generate dietinduced obese (DIO) mice. The normal chow-fed and DIO mice were~14 weeks old. Male BKS.Cg-Dock7 m+/+ Lepr db /J (db/db) and their controls (db/+) were obtained from Charles River Japan (Yokohama, Japan). Male insulin receptor substrate (Irs)-2 deficient mice (IRS-2 2/2 mice) (15) and male heterozygous pancreatic b-cell-specific glucokinase knockout mice (bGck +/2 mice) (16) , which were backcrossed with C57BL/6J mice more than 10 times, were~8 weeks old. Male B6.Cg-Lep ob /J (ob/ob) and their controls (lean; ob/+ or +/+ ), which were obtained from Charles River Japan, were 8 weeks old. All the db/db, IRS-2 2/2 , bGck +/2 , and ob/ob mice and their controls were fed normal chow. All the experiments were conducted using male littermates. All the animal procedures were performed in accordance with the National Institutes of Health Principles of Laboratory Animal Care, Institutional Animal Care Guidelines, and the guidelines of the Animal Care Committee of the Yokohama City University (YCU) (approval no. F-A-13-043). The animal housing rooms were maintained at a constant room temperature (25°C) and a 12-hour light (7:00 AM), 12-hour dark (7:00 PM) cycle.
Drugs
Liraglutide in premanufactured subcutaneous injection pens were obtained from Novo Nordisk (Bagsvaerd, Denmark). Saline solution was used as the vehicle control. OSI-906 (linsitinib) was obtained from Selleck Chemicals (Houston, TX) and Chemscene (Monmouth Junction, NJ). Solutol HS-15 (BASF, Ludwigshafen am Rhein, Germany) was used as the vehicle control. STZ was obtained from Wako Pure Chemical Industries (Osaka, Japan). For the proteomic analysis, we treated male db/db mice with liraglutide or with a vehicle as twice daily subcutaneous injections (9:00 AM and 9:00 PM) for 2 weeks from 4 weeks of age (n = 5 per each group) in the following manner: 0.1 mg/kg on the first day (day 1), 0.2 mg/kg on the second day (day 2), and 0.3 mg/kg as the maintenance dose from the third day until the end of the experiment (days 3 to 14) and collected the blood samples from them at day 15. We also administrated the OSI-906 (7.5 mg/kg) or vehicle to male 8-week-old C57BL/6J wild-type mice once daily for a week, and collected the blood samples from them at day 8. We injected male 13-or 14-week-old C57BL/6J wild-type mice intraperitoneally with STZ (150 mg/kg) or vehicle (saline) and collected the blood samples from them at day 14. No adverse effects on the survival rate were observed during the experiments. Mice were randomly allocated to receive the drug treatment or vehicle in the experiments.
Sample preparation
Whole blood was allowed to clot for 30 minutes at room temperature, then centrifuged at 2000g for 10 minutes at 4°C. We immediately stored the resulting supernatants as serum samples at 280°C until use. For the proteomic analysis, we collected the serum samples from 4-, 8-, 12-, and 24-week-old male db/db mice (n = 4 for 4-, 8-, and 24-week-old; n = 6 for 12-week-old) and db/+ mice (n = 4 for 4-to 24-week-old) [ Fig.  1(a) ] and db/db mice treated with liraglutide or vehicle (n = 5 per each group) [ Fig. 2(a) ]. We depleted seven highly abundant serum proteins [albumin, a1-antitrypsin, transferrin, fibrinogen, immunoglobulin G, immunoglobulin M, and haptoglobin] from 10 mL of the serum samples using immunoaffinity columns (Seppro Mouse Spin Columns; Sigma-Aldrich, St. Louis, MO), as described by the manufacturer. The depleted serum proteins were precipitated by three volumes of cold acetone and redissolved in 8 M urea HEPES buffer [8 M urea and 20 mM HEPES (pH 8.0)]. A total of 10 mg of proteins, which were quantified using a Bradford assay, were reduced with 10 mM dithiothreitol, alkylated with 25 mM 2-iodoacetamide, and diluted with three volumes of 20 mM HEPES buffer (pH 8.0). The proteins were digested by incubation with trypsin (protein-toenzyme ratio of 20:1) for 18 hours at 37°C. The protein digests were then desalted using C18 StageTips (17) and evaporated in a vacuum concentrator.
Shotgun liquid chromatography-tandem mass spectrometry, peptide identification/quantitation, and gene ontology analysis
The peptide loading volume [around one-tenth of the peptides reconstituted with 65 mL of 0.1% trifluoroacetic acid (0.15 mg/mL protein)] was adjusted based on the results of the preliminary liquid chromatography-tandem mass spectrometry (LC-MS/MS) run to limit the signal intensity of major peptide peaks below saturation level. Peptides were separated using a C18 reverse-phase column with a linear gradient of mobile phase B from 2% to 33% for 120 minutes and at 95% of B for 10 minutes [mobile phase A: 2:98 (volume-to-volume ratio) acetonitrile/water; mobile phase B: 95:5 (volume-to-volume ratio) acetonitrile/water, both of which were supplemented with 0.1% formic acid] at a flow rate of 300 nL/min and were and db/+ mice at each age in experiment 1 (n = 4; 4-, 8-, and 24-week-old db/db mice, n = 6; 12-week-old db/db mice, n = 4; 4-to 24-week-old db/+ mice). (f) A four-way Venn diagram shows the total number of proteins detected in db/db mouse sera at each age in experiment 1. (g and h) A four-way Venn diagram shows the number of (g) upregulated or (h) downregulated proteins in db/db mouse sera, compared with that in db/+ mouse sera, at each age. Values represent mean 6 standard error. **P , 0.01.
analyzed using an LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). The peptides were electrosprayed with an electrospray ionization source with the spray voltage of 1.8 kV. Dynamic exclusion was performed with exclusion duration of 180 seconds using a 5-ppm window and resolution of 60,000. Tandem mass spectra (350 to 1200 m/z) were obtained in a data-dependent scanning mode for the 15 most-intense ions selected from the MS-scan spectrum. The normalized collision energy was set to 35%.
A quantitative data analysis was performed using Progenesis QI software (Nonlinear Dynamics, Newcastle, UK) by the automatic alignment of the retention times for all the peptide peaks. The features were then filtered according to charges of +2, +3, and +4 and normalized with their experimental variations by a normalization factor calculated with the median and absolute deviation approach. Multivariate statistical analysis was performed by dividing the samples into two groups: db/db and db/+ mice in experiment 1 or db/db mice treated with or without liraglutide in experiment 2. MS/MS ion searches to identify proteins were performed using MASCOT software (version 2.4.1, Matrix Science, London, UK) against the UniProtKB database (http://www.uniprot.org/) with the following parameters: enzyme, trypsin; peptide precursor mass tolerance, 65 ppm; fragment mass tolerance, 60.5 Da; maximum missed cleavages, 2; fixed modification, carbamidomethyl (C); and variable modifications for oxidation (M), carbamyl (K), and carbamyl (N-term). Mascot-integrated decoy database search calculated a false discovery rate ,1% with a peptide ion score .30. The peptide annotations were reimported to the features with the calculated normalized abundances using Progenesis QI. Quantitative proteomic data by Progenesis QI analysis is presented in the Supplemental Tables 1 and 2 .
Proteins with significant quantitative changes were selected according to the calculation with Progenesis QI by applying following parameters: analysis of variance (ANOVA) P value ,0.05, fold change .1.5, q value (false discovery rate adjusted P value) ,0.05, power .80%, and proteins with more than two unique peptides. The power analysis by Progenesis QI also indicated that four replicates would give 80% (12-week-old db/db mouse sera) to 100% (4-, 8-, and 24-week-old db/db mouse sera and liraglutide-treated db/db mouse sera) of our data with power .0.8 (Supplemental Fig. 1 ). Gene ontology (GO) annotations were obtained using a GOSlimViewer (18) at the AgBase database (http://www.agbase.msstate.edu/) with a Generic GO slim set developed from GO consortium (http:// geneontology.org/).
Patient selection
We collected the blood samples of 27 patients who had T2DM and 15 nondiabetic control subjects with obesity and/or endocrine disease admitted to YCU Hospital between January and September 2016. All the patients were older than 20 years and younger than 70 years of age. Patients with severe complications including liver disease, renal dysfunction with a baseline estimated glomerular filtration rate of ,30 mL min 21 
m
22 , severe ketosis or diabetic coma, severe infections, perioperative status, or severe trauma were excluded from both the patient and the control groups in this study. Patients who had cancer who were untreated or who were undergoing treatment were also excluded from both the patient and the control groups in this study. The patients who had T2DM treated both with and without antidiabetic medication were included in this study. We excluded the data of serum insulin and homeostatic model assessment of insulin resistance (HOMA-IR) in patients who had T2DM treated with insulin injection from the analyses. The diagnosis of T2DM was based on the Report of the Committee of the Japan Diabetes Society on the Classification and Diagnostic Criteria of Diabetes Mellitus (19) . All the subjects agreed to participate in this study by providing informed consent in accordance with the ethical committee regulations of the YCU Hospital (approval no. B151201003). This study was registered in the UMIN Clinical Trials Registry (UMIN000020474).
Biochemical parameters
We used a commercial enzyme-linked immunosorbent assay (ELISA) kit and measured the serum EGFR levels in mice (Abcam, Cambridge, UK; catalog no. ab201275) and humans (R&D Systems, Minneapolis, MN; catalog no. DEGFR0) according to the manufacturers' instructions. Intra-and interassay coefficients of variation were 1.9% and 8.5% for mouse EGFR, and 3.7% to 5.5% and 9.4% to 10.0% for human EGFR, respectively. The plasma glucose levels and the serum insulin levels in mice were determined using a Glutest Neo Super (Sanwa Kagaku Kenkyusho, Nagoya, Japan) and an insulin ELISA kit (Morinaga, Yokohama, Japan; catalog no. M1102). HOMA-IR, a marker of insulin resistance (20) , is calculated as fasting insulin (mIU/mL) 3 fasting glucose (mg/dL)/405. C-peptide immunoreactivity (CPR)-index, a marker of insulin secretion capacity (21) , is calculated as fasting CPR (ng/mL)/fasting glucose (mg/dL) 3 100.
Real-time polymerase chain reaction
Total RNA was isolated from the liver tissue using a QIA shredder and an RNeasy kit (QIAGEN, Hilden, Germany). Total RNA was isolated from the epididymal fat using an RNeasy lipid tissue kit (QIAGEN). Complementary DNA was prepared using High Capacity complementary DNA reverse transcription kits (Applied Biosystems, Foster City, CA) and was subjected to quantitative polymerase chain reaction (PCR; 7900 real-time PCR system; Applied Biosystems, Foster City, CA) using THUNDERBIRD SYBR Quantitative PCR Master Mix (Toyobo, Osobo, Japan). Each quantitative reaction was performed in duplicate. Data were normalized according to the b-actin level. The primer sequences were used as follows: Egfr forward primer: 5 0 -GCCATCTGGGCCAAAGATACC-3 0 ; Egfr reverse primer:
Statistical analysis
Data were tested for normal distribution using the Kolmogorov-Smirnov test. Parametric data were reported as the mean 6 standard error. Nonparametric data were reported as the median (interquartile range). Categorical variables were compared by x 2 test. The differences were examined with Student t test, ANOVA, or Mann-Whitney U test, and correlations between parameters were explored with Pearson (r) or Spearman (r s ) correlation, respectively, depending on the normality of data distribution. Significance was defined if the P value was ,0.05 (*) or ,0.01 (**). Statistical analyses were performed with SPSS version 19.0 (IBM Corporation, NY).
Results
Serum proteome profiles of db/db vs db/+ mice at 4, 8, 12, and 24 weeks of age
We first collected serum samples from male db/db mice at 4, 8, 12, and 24 weeks of age and from age-matched db/+ mice as a control group and analyzed the serum proteins in these samples using a comparative proteomic analysis with label-free LC-MS/MS [ Fig. 1(a) ; experiment 1]. At 8 weeks of age, the db/db mice had developed morbid obesity and severe hyperglycemia [ Fig. 1(b) and 1(c) ]. Hyperinsulinemia was observed in db/db mice at 4, 8, and 12 weeks of age but had disappeared at 24 weeks of age [ Fig. 1(d) ]. HOMA-IR also increased in db/db mice at 4, 8, and 12 weeks of age, but the significance of the change disappeared at 24 weeks of age [ Fig. 1(e) ]. Thus, obesity and diabetes were manifested at 8 weeks of age and hyperinsulinemia had disappeared at 24 weeks of age because of b-cell failure.
As potential candidates for serum biomarkers that are consistently associated with diabetes regardless of disease progression, we focused on 157 proteins with overlapping expressions in db/db mouse sera across all ages [ Fig. 1(f) in bold] . These proteins included adiponectin and retinol-binding protein 4, which are circulating biomarkers related to obesity and insulin resistance [Supplemental Fig. 2(a) and 2(b) ]. Serum proteins that were significantly upregulated or downregulated in db/db mouse sera at earlier stages of diabetes (4 to 8 weeks of age) included four upregulated and eight downregulated proteins in db/db mice at 4 weeks of age and three upregulated proteins and two downregulated proteins in db/db mice at 4 and 8 weeks of age (fold change .1.5, ANOVA, P , 0.05) [ Fig. 1(g) and 1(h), in underline] . A GO analysis suggested that these early stage-specific proteins were related to ion binding, lipid binding, or peptidase activity (Supplemental Fig. 3 ; Supplemental Table 3 ). The significant upregulation or downregulation of these proteins was assumed to reflect the early progression of hyperglycemia, hyperlipidemia, insulin resistance, or b-cell compensation before the manifestation of diabetic complications.
On the other hand, nine proteins (antithrombin-III, C-reactive protein, fructose-bisphosphate aldolase B, serum albumin, apolipoprotein A-II, apolipoprotein C-II, apolipoprotein C-III, mannan-binding lectin serine protease 2, and thyroxine-binding globulin) were significantly upregulated, and 11 protein (isoform 2 of complement factor D, MCG15829, isoform CRA_a, haptoglobin, L-selectin, a-1-antitrypsin 1-5, EGFR, complement component C8 a chain, complement component C8 b chain, complement component C8 g chain, complement C1s-A subcomponent, and vascular cell adhesion protein 1) were significantly downregulated in db/db mouse sera at least more than three among four points of ages (4, 8, 12 , and 24 weeks of age) (fold change .1.5, ANOVA, P , 0.05) [ Fig. 1(g ) and 1(h) in bold, as a control group for 2 weeks, then analyzed the serum proteins using the same proteomic method as that described for experiment 1 [ Fig. 2(a) Among a total of 201 serum proteins that were subjected to label-free quantification using LC-MS/MS, 7 proteins were significantly increased and 1 was significantly decreased in db/db mouse sera treated with liraglutide (fold change .1.5, ANOVA, P , 0.05) ( Table 2 ). All of these proteins were overlapped with 157 proteins that were detected in 4-, 8-, 12-, and 24-weekold db/db mice in Fig. 1(f) . Furthermore, the abundance Fig. 4(a) ] that were commonly identified in experiment 1 and experiment 2. The circulating levels of those proteins were reduced in db/db mice and those levels were restored by the treatment with liraglutide [ Fig. 3(a) and (b); Supplemental Fig. 5(a)-5(j) ]. Except for EGFR, other five proteins are involved in inflammation and complement system. These changes of protein levels were assumed to reflect the chronic microinflammation and complement dysregulation in db/db mice. Obesity and insulin resistance, that are characteristics of db/db mice, induce the chronic microinflammation and complement dysregulation as previously reported (22, 23) . Complement factor D, also known as adipsin, is an adipokine that improves the b-cell function, and is decreased in the sera of patients who have T2DM with b-cell failure (24) . The serum levels of EGFR were significantly reduced in db/db mice throughout to 24-week-old (fold change .1.5 in 4-, 8-, and 12-week-old and fold change =1.33 in 24-week-old, ANOVA, P , 0.05), and those levels were restored by the treatment with liraglutide (fold change =2.00, ANOVA, P , 0.05) [ Fig. 3(a) and 3(b) ]. We validated the serum sEGFR levels in mice using an ELISA assay [ Fig. 3(c) and  3(d) ], and then focused on EGFR for further analyses.
EGFR expression levels in the tissue and sera from diabetic mice
Next, we investigated the messenger RNA (mRNA) expression levels of Egfr in the liver and adipose tissue [ Fig. 3(e) and 3(f) ], which were also significantly lower in the db/db mice than in the db/+ mice. In the liraglutidetreated db/db mice, the mRNA expression of Egfr was significantly increased in the liver. Liraglutide also increased Egfr expression in adipose tissue in db/db mice [ Fig. 3 (e) and (f)].
We also measured the serum sEGFR levels in several diabetic mouse models using an ELISA [ Fig. 4(e) ]. The body weight, casual blood glucose, serum insulin levels, and HOMA-IR of IRS-2 deficient mice (IRS-2 2/2 mice), which exhibit a reduced proliferation of b-cells and insulin resistance (15), of heterozygous pancreatic b-cellspecific glucokinase knockout mice (bGck +/2 mice), which exhibit impaired insulin secretion in response to glucose (16) , of DIO mice, of ob/ob mice, and of STZinduced diabetic mice (after the single intraperitoneal injection of 150 mg/kg of STZ) were described [ Fig.  4(a)-4(d) ]. The IRS-2 2/2 mice exhibited hyperglycemia accompanied by increases in the serum insulin levels and HOMA-IR, whereas the bGck +/2 mice and STZ-induced diabetic mice exhibited hyperglycemia because of reduced insulin levels. The DIO and ob/ob mice exhibited obesity, and severe insulin resistance compared with IRS-2 2/2 mice. The serum sEGFR levels were significantly reduced in the DIO mice and ob/ob mice, and increased in the bGck +/2 mice and STZ-induced diabetic mice, compared with the respective control mice. We next measured the serum sEGFR levels in mice treated with OSI-906, a dual inhibitor of IGF-1 receptor and insulin receptor, using an ELISA [ Fig. 4(f) ]. The OSI-906-treated mice exhibited hyperglycemia and hyperinsulinemia because of impaired insulin signaling (25) . After the daily administration of 7.5 mg/kg of OSI-906 for a week, the serum sEGFR levels were elevated, compared with those in animals treated with the vehicle alone.
sEGFR expression levels in sera from patients who have T2DM
We measured the sEGFR levels in sera from 15 normal glucose tolerance (NGT) subjects and 27 patients who had T2DM using an ELISA (Table 3) . Among the NGT subjects, no correlations were observed between the serum sEGFR levels and any other parameter. However, the serum sEGFR level was significantly correlated with age, body mass index, systolic blood pressure, fasting blood glucose, total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) levels in patients who have T2DM (Table 4 ). The serum sEGFR levels were also positively correlated with the fasting blood glucose, fasting serum insulin, HOMA-IR, HbA1c, TC, LDL-C, and triglycerides (TG) levels in all the subjects, including the NGT subjects and the patients who have T2DM (Table 4) . To exclude the influences of the antidiabetic medication, we also analyzed subjects except for patients with antidiabetic medication. However, the number of drug-naïve patients who have T2DM was too small to analyze (Supplemental Table 4 ). Then we analyzed the patients with T2DM who were not treated with insulin sensitizers (biguanides or thiazolidinediones) and NGT subjects. Serum sEGFR levels also showed the positive correlation with the fasting blood glucose, fasting serum insulin, HOMA-IR, HbA1c, and TG levels in those subjects (Supplemental Tables 5 and 6 ) as well as all the subjects including the whole patients who have T2DM and NGT subjects (Table 4) .
Discussion
In this study, we performed serum proteomic analyses and detected 20 circulating proteins that showed differences in protein abundance in db/db mice at 4, 8, 12, and 24 weeks of age, compared with the levels in db/+ mice. We also identified eight serum proteins whose protein levels were modified by liraglutide treatment in db/db mice. Among these proteins, overlapped six proteins were decreased in db/db mice, and those levels were restored by the treatment with liraglutide. In this paper, we focus on EGFR and provide evidence that serum sEGFR is correlated with insulin resistance in both mice and humans. EGFR, a transmembrane tyrosine kinase receptor, is a member of the ErbB family, and expressed on various cell types of epithelial, mesenchymal, and neuronal origin (26) . EGFR is activated by binding to several different ligands, resulting in receptor dimerization as a homodimer or as a heterodimer with other ErbB members, and the transphosphorylation of tyrosine residues within the intracellular domain of EGFR. Ligand-induced EGFR signaling leads to the activation of several downstream pathways including the Ras/Raf/mitogen-activated protein kinase pathway, which regulates cell proliferation and survival, and the phosphatidylinositol 3-kinase/Akt pathway, which is involved in cell growth, apoptosis resistance, invasion, and migration (27, 28) . EGFR is also involved in cancer cell survival, proliferation, metastasis, and angiogenesis (29) . In terms of the roles of EGFR in glucose metabolism, EGFRdeficient mice exhibit a marked reduction in b-cell proliferation (30) and failure to expand the b-cell mass under conditions, such as nutrient excess or pregnancy (31) (32) (33) . EGFR expression is also suppressed in the liver of db/db mice (34, 35) and in adipose tissue in human patients who have diabetes (36) . EGFR phosphorylation, which was enhanced in diabetic vascular tissue, contributes to diabetesinduced vascular dysfunction (37) . However, the meaning and importance of the serum sEGFR level in diabetes and metabolic syndrome remains unclear. Serum EGFR is detected in patients who have cancer and healthy individuals as a soluble isoform that only contains the extracellular domain of full-length EGFR (38, 39) . All the peptide sequences of EGFR detected by this proteomic analysis were derived from the extracellular domain (Supplemental Table 7 ). Thus, the soluble isoform of EGFR was likely to have been measured in the analysis. sEGFR is generated by alternative splicing (40) or ectodomain shedding (41) and is detected in malignant cells and normal tissue, as well as serum. sEGFR inhibits the tyrosine kinase activity of the EGF receptor by binding to EGF (42) . Recently, Lococo et al. (43) reported that sEGFR was reduced in sera from patients who have non-small cell lung cancer and inhibited cell proliferation in a non-small cell lung cancer cell line, suggesting that sEGFR interfered with EGFR activity by competing for ligands or by binding to EGFR directly (27) . In the field of diabetes and metabolic syndrome, to the best of our knowledge our report is the first to examine the serum sEGFR level in patients who have T2DM.
In this study, the serum sEGFR levels decreased in db/ db, ob/ob, and DIO mice. Because obesity and insulin resistance cause hyperinsulinemia, insulin receptor signaling was chronically activated in these mice. On the other hand, the serum sEGFR levels were elevated in bGck +/2 mice and STZ-induced diabetic mice. bGck
mice and STZ-induced diabetic mice exhibit reduced insulin secretion, resulting in the attenuation of insulin receptor signaling. We also confirmed that OSI-906, which induces glucose intolerance and marked hyperinsulinemia by blocking the insulin receptor signaling pathway (25) , increased the serum sEGFR levels. Thus, we assumed that the serum sEGFR levels were inversely correlated with the activity of insulin signaling, rather than the serum insulin level. Liraglutide treatment increased the serum sEGFR levels in db/db mice, suggesting that excessive insulin receptor signaling was ameliorated by liraglutide. The improvement in insulin sensitivity after liraglutide treatment (13) possibly reduces the insulin signaling overload in db/db mice. Although normal chow-fed IRS-2 2/2 mice exhibited comparable serum sEGFR levels compared with control mice, possibly due to its mild phenotype, further studies in the model of metabolic diseases such as high fat-diet feeding (44) are warranted. In human sera, however, the sEGFR levels were positively correlated with the HOMA-IR, which contradicts the results observed in db/db, ob/ob, and DIO mice. In humans, the serum sEGFR level might also be correlated with fasting blood glucose, fasting serum insulin, and HbA1c levels, possibly creating a confounding influence that affects the HOMA-IR. In addition, higher TC, LDL-C, and TG levels, which are often present in the patients who have T2DM or metabolic syndrome, were positively correlated with serum sEGFR levels. The reasons for these differences between db/db, ob/ob, and DIO mice and humans remain unknown but might be due to the small sample size of human subjects, the absence of highly obese subjects, and healthy individuals who do not have obesity or endocrine disease among the subjects, the influence of antidiabetic medication, or the possibility that the biological action of sEGFR differs between mice and humans, because the serum sEGFR levels in mice are significantly higher (1000-fold) than they are in humans. The origin and mechanism for the generation and regulation of serum sEGFR in patients who have diabetes remains unknown. However, heparin-binding EGF-like growth factor, a member of the EGF family that is expressed in adipose tissue as a transmembrane protein, is proteolytically cleaved to release a soluble form, which is induced by insulin (45) . Indeed, the plasma heparinbinding EGF-like growth factor level was elevated in obese patients and in patients with coronary artery disease (46), who might have had hyperinsulinemia. Thus, we assumed that sEGFR might also be generated by serum humoral factors, the expressions of which change under diabetic conditions in manners similar to those affecting the expression of serum insulin. Because the expression of EGFR changes in metabolic organs, including adipose tissue and the liver, under diabetic conditions, serum sEGFR may be generated from metabolic organs in patients who have diabetes. Further studies are needed to elucidate the relevant mechanisms.
In this study, we identified that the levels of several complement-associated molecules were significantly altered in experiment 1 and experiment 2, in addition to EGFR. EGFR inhibition regulates the complement activation in human epidermis (47) , and EGFR monoclonal antibody (cetuximab) trigger the complement-mediated lysis in tumor cells (48) . Hence, EGFR might contribute to the complement dysregulation under the diabetic or insulin resistance condition in db/db mice.
In summary, the serum sEGFR level can be used as a biomarker reflecting insulin sensitivity and therapeutic efficacy in patients who have diabetes regardless of the stage of disease progression. To confirm the presence of a correlation between serum sEGFR and insulin sensitivity in humans, further analysis of subjects with and without diabetes, drug-naïve patients, and highly obese patients is needed. The origin and biological role of sEGFR in diabetic serum should be explored further, because such study has the potential to reveal new insights into the pathology of diabetes and to have a useful impact on the development of therapeutic strategies.
